Brief: Insmed Announces Positive Topline Results From Phase 2B Study Of Its Blood Pressure Drug

Insmed

10/06/2025 12:14

June 10 (Reuters) - Insmed Inc INSM.O:

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) AS ONCE-DAILY THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

INSMED INC - 35% PLACEBO-ADJUSTED REDUCTION IN PULMONARY VASCULAR RESISTANCE

INSMED INC: STUDY MET PRIMARY AND ALL SECONDARY EFFICACY ENDPOINTS

INSMED INC - TO ENGAGE WITH FDA FOR PHASE 3 TRIAL DESIGN

INSMED INC - RESULTS SHOW SUSTAINED BENEFIT THROUGHOUT 24-HOUR DOSING PERIOD

INSMED: PLANS TO INITIATE PHASE 3 TRIAL IN PATIENTS WITH PH-ILD BEFORE END OF 2025 AND PHASE 3 TRIAL IN PATIENTS WITH PAH IN EARLY 2026

Source text: ID:nPn9JFsFda

Further company coverage: INSM.O

 ((Reuters.Briefs@thomsonreuters.com;))